Phase 2 N=29 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
Acute T-Cell Leukemia-Lymphoma
Primary: Overall Response Rate — 52 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,895 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
Phase 1 N=11 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
T-Cell Lymphoma Relapsed · Adult T-Cell Leukemia (ATL) · Peripheral T-Cell Lymphoma (PTCL)
Primary: Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) — 2 mcg/kg/dose
Phase 2 N=27 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Adult T-cell Leukemia-lymphoma
Primary: Overall Response Rate (ORR) — 50 percentage of participants with response
Phase 1 N=16 Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Adult T-Cell Leukemia and Lymphoma (ATL) · Adult Peripheral T-Cell Lymphoma (PTCL)
Primary: Incidence of Dose-Limiting Toxicities (DLTs) — 1 participants
Phase 2 N=34 Anti-Tac for Treatment of Leukemia
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Phase 2 N=18 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
Leukemia-Lymphoma, Adult T-Cell
Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants
Phase 2 N=29 Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Phase 2 N=15 Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
Adult T-cell Leukemia-Lymphoma · ATLL
Primary: Number of Participants Achieving Complete Molecular Response in Blood Compartment (CMR) — 3 Participants
Phase 2 N=197 Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
CD19-Positive Neoplastic Cells Present · Recurrent Adult Acute Lymphoblastic Leukemia · Recurrent Chronic Lymphocytic Leukemia
Primary: Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy — 0; 0; 1; 0 Participants
Phase 2 N=18 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Phase 1 N=20 Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Phase 2 N=25 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Phase 2 N=3 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants
Phase 2 N=38 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Mycoses · Sezary Syndrome · Lymphoma, T-Cell, Cutaneous
Primary: Progression-Free Survival (PFS) at 180 Days — 73 percentage of participants
Phase 1 N=23 Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Dose Limiting Toxicity (DLT) — 0; 1; 1 Participants
Phase 1 N=12 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Phase 2 N=10 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=26 A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma
Adult T-Cell Leukemia-Lymphoma
Primary: Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee…
Phase 2 N=300 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg
Phase 2 N=49 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
Phase 3 N=271 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Phase 2 N=57 Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Primary: Disease Free Survival — 1.7 years
Phase 2 N=47 Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Phase 2 N=33 Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Phase 2 N=318 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Leukemia
Primary: Complete Response Rate — 89 percentage of patients